Innate Pharma S.A. (EPA:IPH)
France
· Delayed Price · Currency is EUR 1.810
-0.002 (-0.11%)
Apr 1, 2025, 12:32 PM CET
Innate Pharma Revenue
In the year 2024, Innate Pharma had annual revenue of 20.12M EUR, down -67.36%. Innate Pharma had revenue of 7.78M in the half year ending December 31, 2024, a decrease of -35.66%.
Revenue
20.12M
Revenue Growth
-67.36%
P/S Ratio
7.30
Revenue / Employee
111.17K
Employees
181
Market Cap
151.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 44.29B |
| EssilorLuxottica Société anonyme | 26.51B |
| Sartorius Stedim Biotech | 2.78B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| emeis Société anonyme | 5.43B |
Innate Pharma News
- 12 days ago - Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results - Business Wire
- 4 weeks ago - Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference - Business Wire
- 5 weeks ago - Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion - Seeking Alpha
- 5 weeks ago - Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - Seeking Alpha
- 6 weeks ago - Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome - Business Wire
- 2 months ago - Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
- 2 months ago - Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors - Business Wire
- 2 months ago - Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York - Business Wire